Evidence map›Paper›PMID 41822255›Full record

ArticleCureus2026

A Diagnostic Pitfall: Carbamazepine-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Masquerading As Angiotensin-Converting Enzyme Inhibitor Angioedema.

Roberto R Gonzalez Alvarez

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Roberto R Gonzalez AlvarezInternal Medicine, Cape Coral Hospital, Cape Coral, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome (DIHS), is a severe, multiorgan, delayed hypersensitivity reaction with significant morbidity. Diagnosis is often delayed due to its mimicry of other conditions. We present the case of a 69-year-old Hispanic male with hypertension and stage two chronic kidney disease who developed trigeminal neuralgia and was started on carbamazepine. Approximately seven weeks later, he presented with a generalized rash, angioedema, and mucosal swelling, initially attributed to his concurrent lisinopril therapy. Despite discontinuation of lisinopril and treatment with corticosteroids and antihistamines, his condition progressed with new systemic symptoms, including paresthesia, dysgeusia, polydipsia, polyuria, and weight loss. The progression of symptoms despite this intervention was the pivotal diagnostic clue. Hospital admission revealed marked eosinophilia (8.9 percent), mild transaminitis, and a diffuse erythrodermic rash involving more than 90 percent of his body surface area. A diagnosis of probable DRESS syndrome (RegiSCAR score six) secondary to carbamazepine was made. Immediate discontinuation of carbamazepine and initiation of intravenous corticosteroids led to rapid clinical and laboratory improvement. He was discharged on a prolonged oral steroid taper with complete resolution at follow-up. This case underscores the critical importance of considering DRESS in any patient with a rash and systemic symptoms occurring two to eight weeks after initiation of a high-risk drug, even in the presence of other potential culprits. It highlights that clinical progression despite withdrawal of one suspected agent should prompt urgent re-evaluation for an alternative etiology, such as DRESS.

Indexed as

carbamazepinecorticosteroidsdress syndromedrug allergydrug reaction with eosinophilia and systemic symptomseosinophiliahypersensitivity

Identifiers

PMID41822255
PMCPMC12978419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.